Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Second-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma (PDAC) that progresses following gemcitabine-based treatment has not been established. This study aimed to investigate the efficacy and safety of second-line combination chemotherapy with capecitabine and oxaliplatin (XELOX) in these patients. Methods: Between August 2011 and May 2014, all patients who received at least one cycle of XELOX (capecitabine, 1,000 mg/m2 twice daily for 14 days; oxaliplatin, 130 mg/m2 on day 1 of a 3-week cycle) combination chemotherapy for unresectable or recurrent PDAC were retrospectively recruited. The response was evaluated every 9 weeks, and the tumor response rate, progression-free survival and overall survival, and adverse events were assessed. Results: Sixty-two patients were included; seven patients (11.3%) had a partial tumor response, and 20 patients (32.3%) had stable disease. The median progression-free and overall survival were 88 days (range, 35.1 to 140.9 days) and 158 days (range, 118.1 to 197.9 days), respectively. Patients who remained stable longer with frontline therapy (≥120 days) exhibited significantly longer progression-free and overall survival. The most common grade 3 to 4 adverse events in patients were vomiting (8.1%) and anorexia (6.5%). There was one treatmentrelated mortality caused by severe neutropenia and typhlitis. Conclusions: Second-line XELOX combination chemotherapy demonstrated an acceptable response and survival rate in patients with advanced PDAC who had failed gemcitabinebased chemotherapy.
Abstract
Background/Aims: Second-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma (PDAC) that progresses following gemcitabine-based treatment has not been established. This study aimed to investigate the efficacy and safety of second-line combination chemotherapy with capecitabine and oxaliplatin (XELOX) in these patients. Methods: Between August 2011 and May 2014, all patients who received at least one cycle of XELOX (capecitabine, 1,000 mg/m2 twice daily for 14 days; oxaliplatin, 130 mg/m2 on day 1 of a 3-week cycle) combination chemotherapy for unresectable or recurrent PDAC were retrospectively recruited. The response was evaluated every 9 weeks, and the tumor response rate, progression-free survival and overall survival, and adverse events were assessed. Results: Sixty-two patients were included; seven patients (11.3%) had a partial tumor response, and 20 patients (32.3%) had stable disease. The median progression-free and overall survival were 88 days (range, 35.1 to 140.9 days) and 158 days (range, 118.1 to 197.9 days), respectively. Patients who remained stable longer with frontline therapy (≥120 days) exhibited significantly longer progression-free and overall survival. The most common grade 3 to 4 adverse events in patients were vomiting (8.1%) and anorexia (6.5%). There was one treatmentrelated mortality caused by severe neutropenia and typhlitis. Conclusions: Second-line XELOX combination chemotherapy demonstrated an acceptable response and survival rate in patients with advanced PDAC who had failed gemcitabinebased chemotherapy.
참고문헌 (29)
- Bilimoria KY, "Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database", Cancer, 110, pp.738~744 (2007)
- Zuckerman DS, "Adjuvant therapy for pancreatic cancer:a review", Cancer, 112, pp.243~249 (2008)
- Siegel R, "Cancer statistics, 2014", CA Cancer J Clin, 64, pp.9~29 (2014)
- Yeo CJ, "Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival: a prospective, single-institution experience", Ann Surg, 225, pp.621~633 (1997)
- Ducreux M, "Cancer of the pancreas:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 26(Suppl 5), pp.v56~v68 (2015)
- Burris HA, "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial", J Clin Oncol, 15, pp.2403~2413 (1997)
- Moore MJ, "Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group", J Clin Oncol, 25, pp.1960~1966 (2007)
- Conroy T, "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer", N Engl J Med, 364, pp.1817~1825 (2011)
- Colucci G, "Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study", J Clin Oncol, 28, pp.1645~1651 (2010)
- Gonçalves A, "BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer", Ann Oncol, 23, pp.2799~2805 (2012)
- Kindler HL, "Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)", J Clin Oncol, 28, pp.3617~3622 (2010)
- Cunningham D, "Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer", J Clin Oncol, 27, pp.5513~5518 (2009)
- Von Hoff DD, "Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine", N Engl J Med, 369, pp.1691~1703 (2013)
- National Comprehensive Cancer Network, "NCCN guidelines for treatment of cancer by site: pancreatic adenocarcinoma (version 2.2015)" (2015), National Comprehensive Cancer Network
- Tsavaris N, "Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabinepretreated advanced pancreatic cancer: a phase II study", Invest New Drugs, 23, pp.369~375 (2005)
- Yoo C, "A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer", Br J Cancer, 101, pp.1658~1663 (2009)
- Chung JW, "Folfox4 as a rescue chemotherapy for gemcitabine-refractory pancreatic cancer", Hepatogastroenterology, 60, pp.363~367 (2013)
- Oettle H, "Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial", J Clin Oncol, 32, pp.2423~2429 (2014)
- Wang-Gillam A, "Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial", Lancet, 387, pp.545~557 (2016)
- Miwa M, "Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue", Eur J Cancer, 34, pp.1274~1281 (1998)
- Cartwright TH, "Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer", J Clin Oncol, 20, pp.160~164 (2002)
- Xiong HQ, "Phase 2 trial of oxaliplatin plus capecitabine (XELOX)as second-line therapy for patients with advanced pancreatic cancer", Cancer, 113, pp.2046~2052 (2008)
- Bayoglu IV, "Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer", Asian Pac J Cancer Prev, 15, pp.7119~7123 (2014)
- Oken MM, "Toxicity and response criteria of the Eastern Cooperative Oncology Group", Am J Clin Oncol, 5, pp.649~655 (1982)
- Sinn M, "Second-line treatment in pancreatic cancer patients: who profits? Results from the CONKO Study Group", Pancreas, 45, pp.601~605 (2016)
- Edge SB, "The American Joint Committee on Cancer:the 7th edition of the AJCC Cancer Staging Manual and the future of TNM", Ann Surg Oncol, 17, pp.1471~1474 (2010)
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- Trotti A, "CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment", Semin Radiat Oncol, 13, pp.176~181 (2003)
- Herrmann C, "Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer", Oncology, 73, pp.335~339 (2007)